

# **Remibrutinib Demonstrated Superior Efficacy vs Placebo With a Favorable Safety Profile in Patients With Symptomatic Dermographism in the Phase 3 REMIND Study**

*Giselle Mosnaim, Ana Maria Giménez-Arnau, Lindsey Finklea, Koremasa Hayama, Michihiro Hide, Johannes S Kern, Moisés Labrador-Horrillo, Philip H Li, Heike Rockmann, Sarbjit Saini, Sebastian Volc, Jinhua Xu, Bin Yang, Alis Burciu, Li Chen, Clarice Field, Sibylle Haemmerle, Karine Lheritier, Miriam Porter, Martin Metz*

***Please use this [LINK](#) to access the abstract after May 31, 2026, once it is available on the congress website***